AUPH Earnings & Financial Statements
Aurinia Pharmaceuticals Inc.
$16.77
+$0.16(+0.93%)
65
Overall
70
Value
63
Tech
63
Quality
Market Cap
$2.21B
Volume
752.27K
52W Range
$10.90 - $19.25
Target Price
$17.75
AUPH earnings and financial statements: Aurinia Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AUPH Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M |
| Cost of revenue | $32.66M | $28.25M | $14.15M | $5.66M | $1.09M |
| Operating income | $106.56M | $9.72M | -$83.31M | -$111.47M | -$180.74M |
| EBITDA | $127.76M | $10.30M | -$58.43M | -$106.35M | -$177.44M |
| Net income | $287.20M | -$2.94M | -$61.26M | -$108.18M | -$180.97M |
| EPS (diluted) | $2.07 | $0.04 | $-0.54 | $-0.76 | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $751.59M | $550.64M | $548.06M | $470.86M | $543.37M |
| Total liabilities | $170.26M | $173.17M | $170.11M | $65.42M | $64.28M |
| Shareholders’ equity | $581.33M | $377.48M | $377.95M | $405.44M | $479.09M |
| Cash and equivalents | $80.21M | $83.43M | $48.88M | $94.17M | $231.90M |
| Long-term debt | $57.22M | $64.30M | $82.01M | $7.15M | $7.68M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $135.66M | $44.39M | -$34.38M | -$79.53M | -$157.69M |
| Free cash flow | $135.41M | $44.11M | -$35.09M | -$79.82M | -$157.69M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AUPH | $16.77 | +0.9% | 752.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aurinia Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW